Biotech "Tweets of the Week"
Post-election Potpourri
(November 14-18, 2016)
Headlines - $ALNY $CRBP $DVAX $GILD $INCY $MDCO $VRX
In the News - $ARWR $EXAS $OCUL $PBYI $PFE $QURE $TSRO $ZIOP $LABU $XBI $IBB #SITC2016 #FCP4C #AHA16
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
Dynavax plunges on FDA rejection of HBV vaccine $DVAX
$DVAX shares fall on FDA rejection of hepatitis b vaccine https://t.co/jyczpEFS1V The adcomm cancellation turned out to be significant.
— Adam Feuerstein (@adamfeuerstein) November 14, 2016
$DVAX expects a Class 2 designation for a resubmission of the BLA, which would result in a target review period of six months.
— Bio Stocks™ (@BioStocks) November 14, 2016
$DVAX..$3.00 down big here pre-mkt. pic.twitter.com/E6bREKFj13
— Sheff (@SheffStation) November 14, 2016
$DVAX PR says they already gave FDA some of the requested analyses - but FDA issues CRL 1 month early w/o reviewing - doesn't add up
— Red Acre Investments (@redacre) November 14, 2016
RBC $DVAX were surprised to see for first time disclosure of cardiac events imbalance in HBV-23 given as one of reasons for CRL PT 4 from 16
— dough (@tgtxdough) November 16, 2016
Corbus up on scleroderma proof of concept data, but question linger $CRBP
$CRBP = Positive P2 in scleroderma - https://t.co/D14KgqHSVj
— BioNap (@JNapodano) November 14, 2016
Updating $CRBP, up 95%https://t.co/WCn1P1UOeW
— John Carroll (@JohnCendpts) November 14, 2016
$CRBP - $1 to $13 in less than a year , amazing
— BioAlert (@biotrader4gain) November 14, 2016
Was skeptical on $CRBP as I would be any new treatment for SS. Hope to be wrong. Color on data important as CRISS is new, complex
— I.M.Opinion (@subset_member) November 14, 2016
$CRBP how many stat they run to find one that hit p<0.05?
— Andy Biotech (@AndyBiotech) November 14, 2016
1) 1ry endpt changed from 12wk to 16wk
2) median vs mean
3) 1-sided MMRM
4) mITT
out $CRBP tiny profit. too many questions.
— Kent Dorfman (@olddoggnewtrix) November 14, 2016
$CRBP..$9.70 now up only 67%. Now only up 67%? I will take that return all day long:)
— Sheff (@SheffStation) November 14, 2016
JT-101 is another drug thats been around for years and never “made it”. Latest $CRBP data top-line positive but hardly overwhelming
— David Grainger (@sciencescanner) November 15, 2016
RNAi product for PCSK9 passes early test $MDCO $ALNY
$MDCO $ALNY PCSK9 data out at #AHA16 https://t.co/lKIuIv6lrB
— Andy Biotech (@AndyBiotech) November 15, 2016
Focus will be on the safety details not mentioned in PR
Our @benthefidler on latest PCSK9 data. Could b a 2x/yr inject. Current drugs getting little traction. Y would this? https://t.co/b1ArNsu0K8
— Alex Lash (@alexlash) November 15, 2016
$MDCO providing weirdly granular info on that single death: a patient chose dinner over a doctor and died as a result
— Damian Garde (@damiangarde) November 15, 2016
$ALNY- $MDCO solid, uneventful PCSK9 data. Problem for $MDCO will be to maintain investor interest until phase III read-outs.
— Dirk Haussecker (@RNAiAnalyst) November 15, 2016
Listening to $MDCO call now. Meanwell doesn't hide behind coded words: "License it. Buy us. Great investment!"
— Jon Gardner (@ByJonGardner) November 16, 2016
Gilead's cold streak in the clinic continues $GILD $INCY
$GILD racks up another R&D setback as #myelofibrosis drug flounders in PhIII https://t.co/xsiB8xJvJb ->subscribe-> https://t.co/dp0dmhrawI
— ENDPOINTS (@endpts) November 16, 2016
@dsobek Filgotinib for sure. GS-5745 (MMP9) much less degree. ASK-1 question mark. Others too early stage.
— JQ (@jq1234t) November 16, 2016
$GILD could have bought $INCY this spring and still had $15B in the bank. Billion with a B.
— Jake King (@FajaJake) November 16, 2016
Jefferies' Brian Abrahams wins analyst note title of the day w $GILD-- "mo'-melotinib, mo' problems" pic.twitter.com/mjU9OYqX0s
— Meg Tirrell (@megtirrell) November 16, 2016
$GILD rant 1/: I am contrarian on $GILD. Making an overpriced acquisition that won't cover cost of capital is worse thing $GILD can do.
— exMBB (@exMBB) November 17, 2016
$INCY PT Bumped to $115 at Leerink as $GILD's Momelotinib Disappointshttps://t.co/3kV6oqSnh6
— Bio Stocks™ (@BioStocks) November 17, 2016
So what biotech company has been sold in past two years that Gilead should have bought? What price should they have paid?
— Charley Grant (@CGrantWSJ) November 17, 2016
Another big shoe drops in Valeant - Philidor saga $VRX
Update: US announces criminal charges in connection to Valeant probe; ex-VRX exec. Tanner & ex-Philidor CEO Davenport charged
— CNBC Now (@CNBCnow) November 17, 2016
federal fraud and kickback charges - https://t.co/MzCPPA2Mgl $VRX
— zach (@zbiotech) November 17, 2016
Key passage from complaint against former Philidor mail-order pharmacy officials, alleging they worked together to gain $VRX's business pic.twitter.com/LRlOs8uhZ5
— Jonathan Rockoff (@jonathanrockoff) November 17, 2016
Wow. The one being defrauded here, allegedly, is...Valeant. https://t.co/n2UpRco46Y
— Caroline Chen (@CarolineYLChen) November 17, 2016
Interesting choice of words in Valeant statem: Company, former CEO, former CFO, current executives have not been charged *at this time* $VRX
— David Crow (@bydavidcrow) November 17, 2016
As seen on the stream
The best article you'll read about $PFE's Celebrex study https://t.co/PZBr4HrWG0 by @matthewherper
— Lisa LaMotta (@BioWriterChik) November 13, 2016
Today's Google Doodle honors Frederick Banting, the discoverer of insulin. https://t.co/hmafCIYFig pic.twitter.com/w2XlQuCuhT
— Brad Loncar (@bradloncar) November 14, 2016
$OCUL Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from P3 Clinical Trial of DEXTENZA™ https://t.co/VCI15j84Et
— Odi (@odibro) November 14, 2016
Too funny... RT @bradloncar: $EBIO earns a penalty flag for flagrant use of the word "exciting" in their press release.
— Sally Church (@MaverickNY) November 14, 2016
Got a winner $crbp and a loser $dvax will hold on to dvax for a better entry point to avg down
— Pharm. D (@Pharmdca) November 14, 2016
Wrote a long thing on developing the Duchenne pipeline after eteplirsen: Can a consensus be reached on trials? https://t.co/ivdyRai1Z6
— Lisa Jarvis (@lisamjarvis) November 14, 2016
$ARWR RNAi with ARC-AAT provides deep &prolonged
— Joe (@GantosJ) November 14, 2016
knockdown of alpha-1antitrypsin lvls in healthy volunteers #AASLD16 https://t.co/Hn1uJwshPJ
*ALNY: SANOFI GENZYME WILL CO-DEVELOP,CO-COMMERCIALIZE FITUSIRAN $ALNY
— zach (@zbiotech) November 14, 2016
Small set of patients and early, but @Viralytics combo data presented at #SITC2016 look good https://t.co/nqB60Vgsjn $VLA $VRACY #oncolytic
— Juan P. Serrate, DVM (@JPZaragoza1) November 14, 2016
$PBYI — I’m told the stock is reacting negatively to this neratinib abstract for San Antonio breast cancer mtg —> https://t.co/tC1pVvLaLJ
— Adam Feuerstein (@adamfeuerstein) November 14, 2016
perspective - $PBYI recent secondary (~170M) was/is larger than $CASC EV - as they face continued tox and competition, label/FDA concerns
— zach (@zbiotech) November 14, 2016
@AndyBiotech Capitulation, to the upside apparently...
— Vk (@biotechinvstr) November 14, 2016
$PETX - break out from trading range in progress
— Raj R (@rajramaswamy) November 14, 2016
$LABU $28 ---> $49 1 week, pretty decent... $IBB $XBI ¯\_(ツ)_/¯
— Jean Fonteneau (@JFinDallas) November 14, 2016
$TSRO 1,750,000 shares + 262,000 share greenshoe. Potentially a ~$275M offering.
— Brad Loncar (@bradloncar) November 14, 2016
cue the 'no takeout' talk $TSRO
— zach (@zbiotech) November 14, 2016
$NK just claimed victory for an activated Natural Killer cell study in merkel cell carcinoma based on a single patient’s worth of data.
— Adam Feuerstein (@adamfeuerstein) November 14, 2016
$PTLA data-mines failed APEX study:https://t.co/ehCZzaoaZb
— Roy Friedman (@DewDiligence) November 15, 2016
This will be a pretty good test of how loose the FDA really is.
Trees don't grow to the sky.
— Andy Slavitt (@ASlavitt) November 15, 2016
Drug price shock: Feds reveal how medication costs hit Medicare and Medicaid https://t.co/rijoGjY4co
Looking forward to seeing friends and colleagues at the Jefferies HC conference this week
— Daphne Zohar (@daphnezohar) November 15, 2016
@adamfeuerstein Announced a surprise CART data presentation. https://t.co/LCMQxdSjFA
— Brad Loncar (@bradloncar) November 15, 2016
Our first deep dive at Endpoints, from @tamrasami --
— John Carroll (@JohnCendpts) November 15, 2016
New approaches to de-risking early drug developmenthttps://t.co/VpkvLGL2ZG
$SYN this is going to be ugly. two warrants for every share. Cap structure getting ugly on this one.
— BioHunter (@TheBio_Hunter) November 15, 2016
$QURE to Prioritize Programs in Hemophilia B, Huntington's Disease, Cardiovascular Disease
— Bio Stocks™ (@BioStocks) November 15, 2016
Witty @GSK Volume not a dirty word and need to move focus from price. #FTPharma
— Lisa Urquhart (@LisaEPVantage) November 15, 2016
You wouldn't know it from the way the sector ran this week but today's earnings confirms generics continue to be under pressure
— NathanAaron (@NathanAhron) November 15, 2016
Feel bad for $RPRX - Proellex is actually better than Elagolix in UF but no one will ever trust them 2 get their shit together $NBIX
— Julia Skripka-Serry (@JuliaSkripkaSer) November 15, 2016
$CLDX at a post April blow up high
— Dan Rosenblum (@sharkbiotech) November 15, 2016
. @4thQuarterCap here is a nice explanation of daily compounding on leveraged ETFshttps://t.co/vSw4tqWjbX
— BioBounce.com (@BioBounce) November 15, 2016
.@codytrades Sold the rest of $IBB at open at $292s. Entry was 260. I want to take advantage of this reactionary rally and raise cash.
— Cody (@codytrades) November 15, 2016
$AGN has given back all the Trump biotech rally even as they are in the middle of a large accelerated share buyback.
— David Sobek (@dsobek) November 15, 2016
"Merck has not wavered in our sustained commitment to investing in R&D”, except that it spend $4 billion less on R&D in 2015 than in 2010…. https://t.co/TBoWfnU8Wo
— biotechtoreador (@biotechtoreador) November 15, 2016
Last night's #BCSM transcript - the financial toxicity of cancer - great chat moderated by @stales https://t.co/4aEXBHR22D
— Dr. Deanna Attai (@DrAttai) November 15, 2016
Anyone talking about Public Benefit Corps at #FCP4C? Year after year lots of talk ABOUT patients; where is the action to work WITH patients?
— Ethan O. Perlstein (@eperlste) November 15, 2016
$TRIL fun fact: Baker Brothers now second largest TRIL tute holder....I like that company
— whutrades (@whutrades) November 15, 2016
I believe this project I help lead is DRAMATICALLY improving #CRC patient empowerment for #cancer #Clinicaltrials https://t.co/ZGyBS5sR12
— Tom Marsilje (@CurrentIncurSci) November 15, 2016
. @atulbutte : We're building amazing bio data repositories. Spending next to zero on analysis #FCP4C
— Luke Timmerman (@ldtimmerman) November 15, 2016
"I would not want to have a disease that has a lousy advocacy group," FDA commissioner tells #FCP4C
— Meg Tirrell (@megtirrell) November 15, 2016
FDA's Califf refers to "SCTs: small, crappy trials," often funded by NIH, without validated biomarkers #FCP4C
— Meg Tirrell (@megtirrell) November 15, 2016
Turbulence in biotech, price discovery ongoing, risk reward sets up very nicely for slew of 4Q catalysts, both long and short
— Vk (@biotechinvstr) November 15, 2016
$ACRS opened at $35 out of halt on 50k... now its $24's... OUCH
— Shane Blackmon (@shaneblackmon) November 15, 2016
50 most popular stocks among hedge funds https://t.co/ThoWJXwG49 Very few innovator bios on the list & 1st real one doesn't appear until #13
— David Maizenberg (@biologypartners) November 16, 2016
Chinese scientists become first to test CRISPR in humans, as ‘Sputnik 2.0’ begins: https://t.co/FmhsBufBZj
— FierceBiotech (@FierceBiotech) November 16, 2016
In healthcare didn't see any insider buying on the lows but seeing lots of insider selling at the highs....
— NathanAaron (@NathanAhron) November 16, 2016
Lots of Biotech stocks fighting back delisting threat with reverse stock splits.
— Bursatil Biotech (@BursatilBiotech) November 16, 2016
No-one wants to quit.
$KITE tells me it initially looked at Kochenderfer's NCI work on anti-BCMA CAR. Ultimately decided in-house construct better & unencumbered
— Jacob Plieth (@JacobPlieth) November 16, 2016
$IMUC..$.08..Announces 1 for 40 R/S Split. This was bound to happen considering the stock has been stuck here for awhile.
— Sheff (@SheffStation) November 16, 2016
@JFinDallas winter is coming...
— Chet Stedman (@ChetStedman5) November 16, 2016
I can think of a few biotech companies whose press releases might not make it through the filter if $TWTR starts policing fake news.
— Brad Loncar (@bradloncar) November 16, 2016
Picked up more $petx $sage $srpt
— Pharm. D (@Pharmdca) November 16, 2016
@AF_biotech @ericnym agree IMHO $SAGE is the play. $MRNS will always be play on $SAGE results going forward -poor way to play $SAGE
— dough (@tgtxdough) November 16, 2016
$mrk <Pembro> Lung cancer survivor credits clinical trial for life https://t.co/aBAiujx8cy
— Boaty McBoatface (@srqstockpicker) November 16, 2016
@cardiobrief The ROI on $ invested in HDL modulating therapies has been ungood- I'd spend a day at the races before throwing more $ at this
— Ethan Weiss (@ethanjweiss) November 16, 2016
Glad to see pressure on $MNK re Acthar pricing.No gd randomized trials to support its use + outrageous pricing. Have not used it for 5 years
— Ralph (@StuckInStock) November 16, 2016
Sorry $CLCD, luv ya,but at $40;double your last offering $, you're priced for perfection. Been a great run since $9, but must take profits.
— Phil Kobi (@PhilKobi) November 16, 2016
CFO leaves after less than a year and then a week later the CEO, CSO and COO all sell a ton of shares. $EXAS https://t.co/A81wUA2DIH
— Maxim Jacobs, CFA (@MaxJacobsEdison) November 16, 2016
$XBI $2.3 to 3.6 B of assets in less than a month. Half from flows, half gains.
— Jonathan Robinson (@Robohogs) November 16, 2016
Sometimes it really seems like investors and patients believe in some of these companies far more than their executive & scientific teams do
— David Maizenberg (@biologypartners) November 16, 2016
Biotech Price Movers 11/16:$CARA $FLXN $IMUC $LNTH $STEM $TKAI
— BioPharmCatalyst (@crusadernz) November 16, 2016
Pipeline updates: $HTBX $GTXI $NBRV $SMMThttps://t.co/B50i3L9cnV
Recent offerings:$acrs $65M$bgne $175M + $26M greenshoe $flxn 3.6M shares @ $18
— Joe (@Drchik23) November 16, 2016
@chrissyfarr @DShaywitz Everything in science is promising right up until it is quietly abandoned, wildly successful, or something inbetween
— Jeffrey G. Reid (@jgreid) November 16, 2016
@biotechnova Wouldn't it be nice if that happened. I'd rather see five positive headlines than one big one.
— Brad Loncar (@bradloncar) November 17, 2016
$SNY $REGN continuing on with Praluent pcsk9 CVOT study after interim analysis, @DoniBloomfield reports on @business. Back to waiting.
— Caroline Chen (@CarolineYLChen) November 17, 2016
hmm...LR published an update of AES preview now saying that after speaking to $GWPH mgmt...DDI data may not be presented, something to hide?
— zach (@zbiotech) November 17, 2016
Wall Street not liking the $ZIOP presentation too much: down 2.5% on 15K shares traded
— Biotech 5 (@Biotech_5) November 17, 2016
$bmrn not presenting at ASH - planning to update BMN 270 at biotech meeting in Jan
— Douglas Allan (@Dougallan1) November 17, 2016
Patients have a significant financial stake in treatment they didn't use 2have. A 10% copay 4 $20k per month treatment is $2k/mo #PMConf
— Pearl Freier (@PearlF) November 17, 2016
Listening to $AVIR at Stifel. Per CFO, Vapendavir getting fair amount of partner interest from various pharma w respiratory programs
— Daniel Ward (@danwardbio) November 18, 2016
BREAKING: @NIHDirector Francis Collins confirms that he is stepping down effective January 20. Listen here: https://t.co/FybGqemewx
— FASEB Public Affairs (@FASEBopa) November 17, 2016
Sanofi Halts Production of Bladder Cancer Drug: Drug Shortage to Follow https://t.co/acPi3V8dJm
— daviesbj (@daviesbj) November 18, 2016
A tip of the hat
Excited to announce the launch of Magenta Therapeutics today! See CEO Jason Gardner's "Rebooting The Conversation" https://t.co/Pc2RaAsQtT
— Bruce Booth (@LifeSciVC) November 16, 2016
Tyler Shultz, grandson of Theranos director and former Secretary of State George Shultz, goes on the record. https://t.co/CMsGsfMvrC
— John Carreyrou (@JohnCarreyrou) November 16, 2016
We leave you with this
Zebrafish have astounding ability to repair a severed #spinal cord. Scientists have a new clue to explain how. #NIH https://t.co/IN6BgwWaeR
— Francis S. Collins (@NIHDirector) November 15, 2016
According to RayJay, for the week ending Nov 16, biotech saw the biggest weekly inflows ever, at $2.72B. Previous record= $1.4B, Jan 2015
— Vk (@biotechinvstr) November 17, 2016